Post-transplant lymphoproliferative disorder is a growing complication of kidney transplantation (KT) associated with a dismal prognosis. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a game-changing treatment option modifying the outcome of refractory hematological cancers. Here, we report the case of a 40-year-old KT patient who developed a Burkitt-like Lymphoma with 11q aberration five years after KT. After three unsuccessful lines of chemotherapy, it was decided to treat the patient with anti-CD19 CAR-T cells as a salvage therapy.